Rezultati pretraživanja
  1. P570: Assay the interaction of 1000s of individual T cells and antigen-presenting cells for CAR-T or TCR screening in 24hrs.

  2. 12. ruj 2019.

    Relaxing time for networking work module

  3. 11. srp 2019.

    Thrilling findings on Tregs as prediction and eventually dynamic risk profiling (?!) in breast k patients

  4. 24. svi 2019.

    Checkpoint blockade is turning heads in the oncology community, but only for some patients. Could HSP90 be a solution?

  5. 23. velj 2019.
  6. 1. ruj 2019.

    If you care for immune related-pneumonitis come to see our poster: "P2.04-79 - High Rate of Immune Related Pneumonitis in Lung Cancer Patients Treated with Anti PD-1 Antibodies" 9th Sept 2019 (10:15 - 18:15) at

  7. 23. lis 2019.

    Catch Vigeo CEO, Dr. Jing Watnick’s presentation today at the 2019 BIO Investor Forum happening at 1:00PM ET/10:00 AM PT. Live streaming here:

  8. 15. sij

    Congrats to all the authors involved in these great 3 papers! Check out the awesome News and Views from for a summary New predictors for immunotherapy responses sharpen our view of the tumour microenvironment

  9. 7. stu 2019.

    GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update

  10. 24. sij 2019.

    and specialist is broadening its antibody discovery capabilities by acquiring MAB Discovery’s antibody generation unit.

  11. 28. tra 2019.
  12. 18. sij 2019.

    'Strategies to treat immune hot, altered, & cold tumors with combination immunotherapies' overview (J Galon & D Bruni, 2019).

  13. 14. srp 2019.

    develops models -> assesses how metabolic reprogramming by new therapeutics result in therapeutic outcomes in diseases and

  14. 22. srp 2019.

    investigates model -> assesses how metabolic reprogramming of immune response affects the outcomes of diseases and

  15. 15. lis 2019.

    Investors, don’t miss Dr. Jing Watnick, our CEO, presenting Vigeo’s story at the 2019 BIO Investor Forum next Wednesday, October 23 at 10:00 AM PT. For more details, and a link to the livestream, check out our press release:

  16. 1)Retransplant from a different donor 2)Checkpoint inhibitors 3)IFN-gamma Great work by

    Prikaži ovu nit
  17. 13. sij

    . attended the annual JP Morgan Healthcare Conference in San Francisco yesterday to discuss development and with other .

  18. 13. sij

    Our leadership will be at this week, catching the latest in advances and sharing our pipeline's development and advances towards clinical studies. Wishing the team a productive week in San Fran!

  19. 7. sij

    NEWSLETTER 2020: Reports an exciting 2019 and reveals a look into what's to come in 2020: (2) planned BLA filings in 2L CC (2) Novel discoveries to IND (6) clinical programs with data, including AGEN1181 + balstilimab

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.